I've been a journalist for 30 years, as a senior editor at W magazine, and for the last 17 years, covering retail and real estate as a senior editor at WWD. I write about luxury boutiques, independent retailers, department stores, mass chains, and digitally native brands, and the force that's redefining the way we shop – Amazon.
Ozempic and Wegovy are having an unintended but not entirely unpredictable effect on the apparel industry. Impact Analytics, an AI-based planning and forecasting company, found that the GLP-1 drugs, which are typically prescribed for diabetes but are used by millions for weight loss , are driving down sizes in department and specialty stores. And the issue has implications all along the supply chain.
The Impact Analytics report connects the dots between Ozempic and Wegovy use and clothing sizes and cites the effect of diminishing clothing measurements on retail profit margins. Impact Analytics used data from flagships on Manhattan’s Upper East Side, which it identified as the epicenter of non-diabetic use of GLP-1 drugs. Agrawal predicted a 10% shift in the next five years to smaller sizes.“About 1.5 million Americans are going to get these drugs in the next five years,” Agrawal said. “That’s more than got them in 2023 and there are more new drugs coming.
Impact Analytics said size small has become the most popular size for women on the Upper East Side. Compared to 2022, sales of women’s button-down shirts in small sizes increased in 2024 by 12%, while sales of large sizes decreased by 10.9%.
Fashion Ozempic Slimming Sizes Dresses Stores Boutiques Buyer Customer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FLOW: GLP-1 Kidney Benefits Seen With or Without SGLT2 InhibitorsLarger studies are needed because of the low numbers of patients on SGLT2 inhibitors in the FLOW trial, which showed the kidney benefits of GLP-1 receptor agonists.
Read more »
Pancreatic Gene Therapy: A 'One-and-Done' GLP-1 Treatment?In a mouse model of obesity, a one-time, single-dose pancreatic gene therapy sustained weight loss and glucose benefits that were otherwise reversed with semaglutide withdrawal.
Read more »
GLP-1 Medicine Mounjaro May Be First Drug to Ease Sleep ApneaA medication used to manage type 2 diabetes has been found effective in treating sleep apnea.
Read more »
Beyond Ozempic: New GLP-1 drugs promise weight loss and health benefitsThe World Health Organization issued an alert on falsified versions of Ozempic, the popular drug used to treat type 2 diabetes and obesity. The WHO warned health care professionals and the public to be aware of the counterfeits, which it said are increasing as demand for the drugs grows. NBC News' Anne Thompson reports.
Read more »
In It Together: When Physician and Patient Take GLP-1s for Weight LossWhen physicians on GLP-1s for weight loss disclosed that fact, patients on the drugs said they feel understood, less judged, and not shamed. They may also be more likely to follow the care plan.
Read more »
Bariatric Surgery Beats GLP-1 RAs in Reducing Mortality RiskBariatric metabolic surgery led to 62% greater reductions in mortality than GLP-1 receptor agonists in patients with obesity and diabetes for less than 10 years.
Read more »